High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19.

Antibodies, Neutralizing Antibodies, Viral COVID-19 Female HIV-1 Humans Interferon Type I Interferon-alpha / therapeutic use Male SARS-CoV-2
HIV-1 HIV-1 and SARS-CoV-2 co-infection ISGs Interferon Neutralizing antibodies SARS-CoV-2

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
08 2022
Historique:
received: 10 03 2022
revised: 19 05 2022
accepted: 21 06 2022
pubmed: 29 6 2022
medline: 10 8 2022
entrez: 28 6 2022
Statut: ppublish

Résumé

The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.

Identifiants

DOI: 10.1016/j.clim.2022.109068 PMID: 35764258 PMC: PMC9233547
pubmed: 35764258
pii: S1521-6616(22)00149-8
doi: 10.1016/j.clim.2022.109068
pmc: PMC9233547
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Interferon Type I 0
Interferon-alpha 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109068

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Eur J Immunol. 2022 Feb;52(2):352-355
pubmed: 34822185
Med Intensiva (Engl Ed). 2022 Feb;46(2):98-101
pubmed: 34896032
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Eur J Immunol. 2022 Jul;52(7):1120-1128
pubmed: 35419822
J Infect Dis. 2021 Nov 16;224(9):1455-1461
pubmed: 33825905
Sci Rep. 2022 Sep 13;12(1):14972
pubmed: 36100631
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Aging (Albany NY). 2021 Mar 29;13(7):9265-9276
pubmed: 33780352
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep;13(1):55-67
pubmed: 8797687
Infect Drug Resist. 2021 Sep 28;14:3991-4014
pubmed: 34611416
Biology (Basel). 2021 Aug 26;10(9):
pubmed: 34571706
Front Immunol. 2018 Dec 06;9:2876
pubmed: 30574147
Immunobiology. 2016 Feb;221(2):282-90
pubmed: 26563749
Cytokine Growth Factor Rev. 2018 Apr;40:19-31
pubmed: 29576284
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413139

Auteurs

Mirko Scordio (M)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: mirko.scordio@uniroma1.it.

Federica Frasca (F)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: federica.frasca@uniroma1.it.

Letizia Santinelli (L)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: letizia.santinelli@uniroma1.it.

Leonardo Sorrentino (L)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: leonardo.sorrentino@uniroma1.it.

Alessandra Pierangeli (A)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: alessandra.pierangeli@uniroma1.it.

Ombretta Turriziani (O)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy; Microbiology and Virology Unit, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. Electronic address: ombretta.turriziani@uniroma1.it.

Claudio M Mastroianni (CM)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: claudio.mastroianni@uniroma1.it.

Guido Antonelli (G)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy; Microbiology and Virology Unit, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. Electronic address: guido.antonelli@uniroma1.it.

Raphael P Viscidi (RP)

Department of Pediatrics, Johns Hopkins University School of Medicine, 1800 Orleans Street Baltimore, MD, United States. Electronic address: rviscid1@jhmi.edu.

Gabriella d'Ettorre (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: gabriella.dettorre@uniroma1.it.

Carolina Scagnolari (C)

Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Viale di Porta Tiburtina n° 28, 00185 Rome, Italy. Electronic address: carolina.scagnolari@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Interféron alpha › High frequency of neutralizing antibodies to...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › High frequency of neutralizing antibodies to...